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The first formal conference of the EUropean Federation for Exploratory MEdicines
Development (EUFEMED) held in London was the result of a collaborative effort of
its founding associations: the Association for Applied Human Pharmacology (AGAH;
Germany), the Association for Human Pharmacology in the Pharmaceutical Industry
(AHPPI; UK), the Belgian Association of Phase-I Units (BAPU; Belgium), and Club
Phase-I (France). The conference focused on innovation and risk management
in early clinical drug development. Among other innovations, immunotherapy in
oncology and inflammatory diseases were discussed as well as the importance of
adaptive trial designs in early clinical drug development. Consideration was given
to assessing and mitigating risk in early clinical drug development, and included a
preconference workshop. Different measures to minimize risks in healthy volunteers
and patients in first-in-human trials were discussed in addition to the importance
of non-clinical data, the need for reliable biomarkers, improved communication on
adverse events (AEs) and well-trained study sites with ready access to intensive care
units and clinical specialists. The need for a European-wide system for prevention of
over-volunteering was also discussed. The conference provided opportunity to discuss
these developments and concerns and the changing regulatory environment with
stakeholders from academia, industry, and regulatory agencies including the European
Medicines Agency (EMA). Presentations given by invited speakers are published on
http://www.eufemed.eu/london-conference-2017/.
Keywords: early phase clinical drug development, innovation in drug development, risk mitigation, conference
report, the EUropean Federation for Exploratory MEdicines Development (EUFEMED)
INTRODUCTION
The EUropean Federation for Exploratory MEdicines Development (EUFEMED, www.eufemed.
eu) is a not-for-profit association that aims to improve the early phase clinical drug development
process in Europe. Its first formal conference held in London focused on innovation and risk
management. This report summarizes the key learnings from an audience perspective derived from
the conference.
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PRECONFERENCE 1-DAY WORKSHOP
Practical Aspects of Assessing and
Mitigating Risk in Early Phase Clinical
Trials
The EUFEMED president, Jan de Hoon (University Hospital
Leuven, Belgium) welcomed attendees and explained how the
focus of the workshop topic was a consequence of the Bial
incident in France (Enserink, 2016).
Stephanie Plassmann (Preclinical Safety Consultants,
Switzerland) emphasized the key role of the toxicologist during
drug development, how timely communication between all
disciplines is mandatory and how non-clinical and clinical
development remain closely intertwined. She concluded
that ongoing risk assessments should integrate all data as
they become available, including those from the public
domain.
Friedemann Schmidt (Sanofi, Germany) described
computational systems toxicology and in silico prediction
of off-target activities and how data derived from integrated
in silico methods are gaining regulatory acceptance. As it is
impossible to screen for all off-target effects and since all
methods have their limitations, combining methods can provide
a greater spread of information.
Marc Pallardy (Institut national de la santé et de la recherche
médicale, INSERM, University Paris-Sud, France) spoke about
determination of the first dose for multispecific monoclonal
antibodies. Side effects from the broad range of biologics in
development are very difficult to predict. Low doses have been
implemented in some clinical trials, but these doses are far from
clinically active levels.
Bruno Boutouyrie-Dumont (Novartis, Switzerland) discussed
dose selection based on the minimal anticipated biological effect
level (MABEL) (CHMP, 2007). It was concluded how the first-in-
human dose should be based on available non-clinical data and
on different estimates. Safety assessment should take into account
pharmacodynamic (PD) activity and the duration of action in
man. Protocol development should be a team collaboration and
should, these days, consider the potential for employing an
adaptive design.
Philippe Grosjean and Eric Legangneux (Sanofi, France)
challenged the usefulness of the maximum tolerated dose (MTD)
and its value in developing medicines for humans. It was
questioned why doses must be escalated so high; why take the
risk? Is this approach ethical?
Workshop attendees were privileged to hear from
representatives of regulatory agencies from UK, Belgium,
and Germany. Thomas Sudhop (Bundesinstitut für Arzneimittel
und Medizinprodukte, BfArM, Germany) provided a regulatory
update on the new EU guideline on First-in-Human clinical trials
(CHMP, 2017). The 2007 guideline (CHMP, 2007) was intended
for risk mitigation with high-risk investigational medicinal
products (IMPs) and only covered single ascending dose
administration. The updated guideline covers more complex
designs and also studies in patients. With the Bial trial in mind,
the guideline was developed with safety as the underlying
principle. The guideline should not be seen as mandatory.
But where alternative strategies are requested, full scientific
justifications should be provided.
DAY 1
Keynote: Incidents Happen—Which
Lessons Can We Learn?
Jan de Hoon focused on how incidents have shaped drug
regulation. Most recently, the death of a healthy volunteer in
the Bial trial (Enserink, 2016) led to discussions on how future
trials should be conducted. Over the past 50 years, 12 deaths
have been reported in Phase-I trials worldwide; five were possibly
drug-related, equating to a risk of death of 1 in 500,000 subjects.
To minimize risks, investigators and those working in industry
should have appropriate competence and experience. There
should be improved communication, independent expert review
of data, and measures to prevent over-volunteering. It may also
be advisable to increase the number of inspections conducted
by agencies and the level of accreditations required by sites and
investigators.
Session 1: Managing Risks in Early Phase
Clinical Trials
Ulrike Lorch (Richmond Pharmacology, United Kingdom, UK)
spoke about the revision of the EMA’s guideline on strategies to
identify and mitigate risks for early clinical trials (CHMP, 2017).
When applying the guideline, one should be proportionate to
uncertainty and potential risks, avoid getting stuck in marginal
issues, allow for further investigations where appropriate and use
simple algorithms for potentially fundamental risks. Knowledge,
expertise and an expert team are essential. Training and
clinical pharmacology unit accreditation schemes should be
considered, as well as obtaining scientific advice pre-Clinical-
Trial-Authorization (CTA) submission.
Annick Peremans (Research Centre Aalst, Belgium) asked
how a European-wide system could be established to prevent
over-volunteering. Some healthy volunteers travel from one
country to another, risking drug interactions, uncontrolled
radiation exposure, and unknown consequences for their future
health. There are currently two national databases in Europe: UK
(TOPS) and France (VRB). Belgium/Germany/Netherlands use a
privately owned database (VIPCHECK), but this database is not
used by all institutions. Only a European subject database would
be able to raise the ethical standards and safety of clinical research
in Europe.
Session 2: Scientific Tools in Early
Development of Medicines to Mitigate Risk
Philippe Danjou (Biotrial, France) discussed minimizing risk in
early development of central-nervous-system (CNS) medicines
in the context of the death of a healthy volunteer in the Bial
trial, where the subject was over 50 years of age and had
an underlying pathology that was only detectable on autopsy.
The first option would be to monitor the primary effect or
target occupancy through molecular imaging. However, this
is impossible when relying on animal data alone. Additional
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barriers include the availability of human ligands and cost. If
molecular imaging is not possible, a downstream biomarker is
another option, although the current state of knowledge and
validation of assays may prove to be difficult. Conducting trials
solely in a patient population is a third but unrealistic option.
Healthy subjects frequently tolerate and overcome AEs and
toxicities better than older, co-medicated patients with multiple
pathologies.
An Van den Bergh (Janssen, Belgium) noted that the utility
of physiology-based pharmacokinetics in risk mitigation in early
studies lies in predicting the time profile of drug concentrations
based upon in vitro absorption, distribution, metabolism, and
excretion data along with a plausible biology. It can also
confirm mechanisms governing (non-linear) pharmacokinetics
during dose escalation in the first-in-human ascending dose
studies. It provides an ability to anticipate the impact of genetic
polymorphisms on the pharmacokinetic profile and to anticipate
drug interactions.
Elaine Holmes (Imperial College London, UK) spoke about
the interaction of an individual’s genetic blueprint, the genetics
of the individual’s microflora, and the environment, which could
take the form of food, food additives, drugs, and contaminants.
It is becoming clear that the microbiome plays an important
role in human health. Metabonomic profiling of biofluids (urine,
stool, plasma, vaginal and oral swabs) will help elucidate the
functionality of the microbiome and identify associations with
disease and disease risk.
Session 3: Posters and Oral Presentations
Researchers were given the opportunity to submit abstracts
to be displayed as posters. A selection was presented as
oral presentations. All abstracts are published in http://www.
frontiersin.org/books/EUFEMED_2017/1195.
Session 4: Examples of Innovation and
Risk Management
Jorg Taubel (Richmond Pharmacology, UK) described how
integrated adaptive Phase-I clinical trials are safer, take less
time and cost less than traditional alternatives. He advised
that adaptive designs can establish a “playing field” with set
boundaries on various factors including starting dose, maximum
exposure limits, numbers of subjects, procedures, samples,
and ‘inconveniences.’ They also provide flexibility within the
‘playing field’s’ boundaries to respond to challenges arising
during the trial, all overseen by a safety review committee.
Considering the worst case scenario, adaptive designs are
possible with careful planning and expertise on the part of all
stakeholders.
David Jones (Medicines & Healthcare products Regulatory
Agency, MHRA, UK) explained that it was considered necessary
to revise the 2007 Risk Mitigation guidelines (CHMP, 2007)
after review of the Bial incident. The revision addresses the
evolution of practices in first-in-human clinical trials including
the increasing trend to use integrated protocols. The guideline
emphasizes the critical value of pharmacology and understanding
the mode of action of an IMP. Emphasis should be placed on
estimation of the exposure at the initial dose and following dose
escalations to a predefined maximum exposure. The starting
dose for healthy volunteers should be below the expected
pharmacologically active dose, unless a robust justification for
a higher dose can be provided. The protocol should define
the maximal level of exposure, which is usually based on the
‘no observed adverse effect level’ (NOAEL). By moving from
single to multiple dosing, selection of dosing intervals and
durations should take into account the specific pharmacokinetic
and pharmacodynamic characteristics of the IMP.
Christopher Goldring (University of Liverpool, UK)
presented innovative in vitro models of toxicology assessments
of drug-induced liver injury. Increasingly complex model
systems were presented ranging from single cell two-
dimensional systems, such as primary hepatocytes and
liver-derived cell lines, to three-dimensional systems, such
as multi-cell culture and liver spheroids. A battery test
system can be developed with appropriate refinement and
benchmarking. Multi-dimensional in vitro systems with a
relevant physiological and pharmacological phenotype are also
being progressed.
Alan Boyd (Royal College of Physicians, UK) provided some
examples of innovation and risk management. These included
a gene therapy based product (Cerepro R© in malignant glioma),
molecule repurposing (ACE inhibitors in cancer cachexia), and
an immunotherapy (a bifunctional biologic for treatment of
malignant melanoma). Interestingly, none of these examples
gained marketing authorization. Alan Boyd reported how the
number of new drug applications has been declining steadily over
the last 15 years and concluded that it is crucial to advance new
strategies to reduce the development time frame, decrease costs,
and improve success rates.
DAY 2
Session 5: Assessment and Mitigation of
Risk in Modern Development Strategies for
Paediatrics
Saskia de Wildt (Radboud University Nijmegen, The
Netherlands) gave some historical examples of how poorly
we understand the absorption, metabolism, and clearance
of medicines in children. The benefits of 14C microdosing
were discussed, covering misplaced concerns over exposure to
radioactivity. It was concluded that although there are challenges
yet to be addressed with microdosing, it has the potential to
provide critical information that will empower a more informed
approach to medicine development in children.
An Oxford debate addressed the question of whether
the development of pediatric medicines should be limited
to pharmacokinetic bridging trials alone. The motion was
defended by Clair Aubrey (GlaxoSmithKline, GSK, UK) and
Christoph Male (Medical University Vienna, Austria) countered
the motion. The audience felt that pharmacokinetic bridging
can be useful to predict the dose, but this does not necessarily
extrapolate to the effect a drug may have. Overall, using all the
information available was felt the optimal way to determine the
best dose to be used in children.
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Parallel Workshops
Workshop 1: How to Use the Results from
Non-clinical Studies to Better Predict the Risks in
Early Phase Clinical Trials? Moderator: Stephanie
Plassmann
An integrative approach is needed when considering the various
data from non-clinical testing. Consideration was given to the
values and limitations of commonly determined parameters
such as the MTD, NOAEL, and safety ratio as well as
pharmacokinetic parameters. Emphasis was also placed on
contextualizing findings. The example was that of patients with
neurologic diseases who often tolerate considerably higher doses
than healthy subjects. Finally, an exercise on choosing the starting
dose based on non-clinical data was given. Safety margins should
take into account possible differences in pharmacokinetics (such
as drug absorption and protein binding) and pharmacodynamics
(including susceptibility to develop AEs), between the animal
species and humans.
Workshop 2: Modern Drug Development in
Oncology—How to Successfully Design the Early
Phase Trials? Moderators: Heike Oberwittler (Ipsen,
France) and Sylvie Rottey (Ghent University, Belgium)
The changing face of oncology studies was reviewed in the
context of adaptive trial designs, the use of biomarkers and
novel immunotherapies. It was considered how designing trials
intelligently can facilitate the smooth transition through dose
selection, expansion cohorts and indications—all within a
single adaptive-design Phase-I trial. Development is enhanced
if biomarkers are identified to monitor the activity of a drug.
It might be possible to further refine the study population
with genetic testing, where markers of specific susceptibility can
be determined. Identifying the right dose for cancer patients
remains challenging. Should it be dependent on the size of the
tumor? Labeling and imaging techniques can better identify drug
distribution and delivery to the target site.
The increasing number of clinical trials and targets being
developed are making recruitment of patients to test new agents
increasingly challenging. The possibility of including healthy
volunteers remains limited. In all cases the value of the trial’s
outcome is limited by how dose-limiting toxicities and anti-
tumor activity are assessed.
Workshop 3: Incident Management in Phase-I Trials:
What to Do If Things Go Wrong? Moderators:
Katherina Erb-Zohar (Clinphase; Germany) and Yves
Donazzolo (Eurofins, France)
Focus was first placed on ICH E6(R2), 2016 and its requirements
that foreseeable risks and inconveniences are weighed against. A
trial should be initiated and continued only if the anticipated
risks are and remain acceptable. It is essential to be prepared
for a critical situation, involve staff experienced in managing
emergencies and collaborate with local intensive care providers.
The principal investigator or qualified delegate must always
be available and well-informed of the IMP and the trial,
which should incorporate appropriate stopping rules. It is also
advised that units build relationships with local specialists to
facilitate the provision of support “on-demand” (cardiologist,
neurologists, psychiatrist, etc.). When things do go wrong,
it is essential to manage incidents proactively. Take steps
to avoid symptom progression and prevent harm to other
subjects, follow applicable reporting procedures for serious AEs
and apply appropriate stopping rules. And finally, once the
clinical aspects of the incident have been managed, it is useful
to involve professionals to document and share the lessons
learned.
Session 6: Assessment and Mitigation of
Risk in Trials with Biologicals
Christian Blank (The Netherlands Cancer Institute, The
Netherlands) took the audience on a historical journey from
the 1890s and the ‘fathers’ of the tumor immunology concept
to the early 2000s, covering the theory of immune-surveillance,
the start of clinical trials with anti-‘cytotoxic T lymphocyte-
associated antigen 4’ (CTLA-4) molecules and improved survival
of patients with metastatic melanoma with ipilimumab. The
action of the “programmed death-ligand 1” (PD-L1) and its
upregulation induced by interferon-producing tumor-infiltrating
CD8 T cells was used to introduce the concept of adaptive
immune resistance, the cancer immunogram, and personalized
immunotherapy. The presentation concluded that combinations
of checkpoint inhibitors with short-term targeted therapies
will be the approach most likely to prove successful in the
future.
Ioanis Karydis (University of Southampton, UK) looked at
mitigating immunotoxicity in early phase trials in oncology.
Animal models used to predict toxicity are problematic as they do
not necessarily reflect the host system and there is a pressing need
for predictive biomarkers. Patients are usually highly motivated
and well-informed as well as prepared to accept significant risk
of morbidity and mortality. Consequently, there is a potential to
under-report adverse events. In addition, patients usually have
been heavily pre-treated and express long-term toxicities, making
monitoring challenging. Appropriate care should be taken not
only in designing trials, preferably involving adaptive designs, but
also in selecting study sites. These sites should have competence
and experience in dealing with immune response AEs, and
sufficient resources to deal with the increased burden associated
with adaptive/multi-arm clinical trials, and with a high level of
cross-speciality support.
Ann Gils (Catholic University of Leuven, Belgium) reviewed
immunotoxicity of IMPs for inflammatory disease. Monitoring
of IMP concentrations using enzyme-linked immunosorbent
assays (ELISA), factors influencing their pharmacokinetics and
the incidence of anti-drug antibodies (ADA) were reviewed.
Consideration was given to the differences between non-
neutralizing and neutralizing ADAs, the development of drug
tolerant ADA assays and symptomatic AE profiles associated
with ADA detection using different assays. Early treatment
optimization based on detection of ADAs was discussed in light
of the concept of transient and persistent antibodies. However,
the process is still not fully understood and detection of ADAs is
assay dependent and not always associated with loss of response
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to treatment. Formation of ADAs can be mitigated by using
de-immunizing molecules, adding comedication and increasing
drug exposure.
Geoff Hale (Native Antigen Company, UK) advised how
the guidelines issued by the EMA and the Food and Drug
Administration (FDA) are not fitted to the needs of a rapidly
changing field of study. The example of polyethylene glycol
(PEG) was presented with reference to the unexpectedly high
frequency and titre of immunoglobulin G (IgG) anti-PEG
antibodies observed in healthy populations as a consequence
of the ubiquitous nature of PEG in our environment. This
may have important implications in terms of the use of
PEG in many drug conjugates and the utility of recombinant
control agents. It was concluded that traditional cut-point
approaches to the assessment of pre-existing antibodies are
of little value and alternative approaches are necessary.
Preventing unwanted antibodies via tolerance induction was
discussed and a preview of the positive results of a proof
of concept study inducing tolerance to alemtuzumab was
given.
CONCLUSION
The 2017 EUFEMED conference was well-attended and
facilitated valuable cross-discipline interaction. It has achieved
its objective of focusing on early clinical drug development in a
changing regulatory environment. In closing the meeting, the
president elect, Hildegard Sourgens, summarized how the topics
discussed served to foster a shared appreciation of the innovative
nature of the early clinical development space, and welcomed the
commitment of all parties to addressing concerns over risk and
improving our understanding of the challenges ahead.
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